The 4 analysts offering 12-month price forecasts for Celyad Oncology SA have a median target of 14.38, with a high estimate of 20.00 and a low estimate of 8.03. The median estimate represents a +290.83% increase from the last price of 3.68.
The current consensus among 5 polled investment analysts is to Buy stock in Celyad Oncology SA. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share --
Reporting Date TBD
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.